Loading…

Occurrence Of Skeletal-Related Events (SRE) In Patients With Solid Tumors (ST) And Multiple Myeloma (MM) In Germany: Early Versus Late Initiation of Sre Preventative Agents (SPA)

OBJECTIVES: in patients with ST and bone metastases (BM) or with MM, SREs are serious and common complications impacting life expectancy and quality of life. This exploratory and descriptive analysis estimated the time from diagnosis to occurrence of first and subsequent SRE in patients with early v...

Full description

Saved in:

Bibliographic Details
Published in:	Value in health 2017-10, Vol.20 (9), p.A417
Main Authors:	Intorcia, M, Hohmann, D, Giannopoulou, C, Ansorge, S
Format:	Article
Language:	English
Subjects:	Bisphosphonates Bones Confidence intervals Diagnosis Inpatient care Kidney diseases Life expectancy Life span Medical diagnosis Metastases Metastasis Monoclonal antibodies Multiple myeloma Myeloma Newly diagnosed Osteoporosis Patients Quality of life Solid tumors Targeted cancer therapy Tumors
Citations:	Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by	cdi_FETCH-LOGICAL-c1643-c932d94ec27c58ea9f58d0db7b765ce69070be2b94b386c8e2904b2a2323866a3
cites
container_end_page
container_issue	9
container_start_page	A417
container_title	Value in health
container_volume	20
creator	Intorcia, M Hohmann, D Giannopoulou, C Ansorge, S
description	OBJECTIVES: in patients with ST and bone metastases (BM) or with MM, SREs are serious and common complications impacting life expectancy and quality of life. This exploratory and descriptive analysis estimated the time from diagnosis to occurrence of first and subsequent SRE in patients with early versus late treatment initiation with SPA. METHODS: This was a retrospective analysis of a German sick-fund claims database (covering -4 million patients) which includes data from 2007 to 2015. Patients with a diagnosis of ST coded with at least two outpatient or one inpatient diagnoses and newly diagnosed with BM after 07/2011 and patients newly diagnosed with MM after 07/2011, aged >18 years were included. All patients received either denosumab or bisphosphonates within 9 months from study inclusion. The study described the time from BM or MM diagnosis to occurrence of first and subsequent SRE in patients with early (
doi_str_mv	10.1016/j.jval.2017.08.113
format	article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2113726387</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2113726387</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1643-c932d94ec27c58ea9f58d0db7b765ce69070be2b94b386c8e2904b2a2323866a3</originalsourceid><addsrcrecordid>eNotUctOwzAQjBBIQOEHOK3EhR4S_MiTW4VKQWrVihY4Wo6zhQQ3KXZSKb_FF-IAp33Nzqx2PO-KkoASGt9WQXWQOmCEJgFJA0r5kXdGIxb6YcL5sctJlvqc0OjUO7e2IoTEnEVn3vdSqc4YrBXCcgvrT9TYSu0_o5YtFjA9YN1auFk_T8fwVMNKtuVv561sP2Dd6LKATbdrzIDZjGFSF7DodFvuNcKiR93sJNwsFr_LMzQ7Wfd3MJVG9_CKxnYW5k7ITcu2dNxNDY07wyCsDA7arndAmLz_n7GajC-8k63UFi__48h7eZhu7h_9-XL2dD-Z-4rGIfdVxlmRhahYoqIUZbaN0oIUeZIncaQwzkhCcmR5FuY8jVWKLCNhziTjzNWx5CPv-o93b5qvDm0rqqYztZMUzD04YTFPE4difyhlGmsNbsXelDtpekGJGLwRlRi8EYM3gqTCrfIf7LWCLg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2113726387</pqid></control><display><type>article</type><title>Occurrence Of Skeletal-Related Events (SRE) In Patients With Solid Tumors (ST) And Multiple Myeloma (MM) In Germany: Early Versus Late Initiation of Sre Preventative Agents (SPA)</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>Elsevier</source><creator>Intorcia, M ; Hohmann, D ; Giannopoulou, C ; Ansorge, S</creator><creatorcontrib>Intorcia, M ; Hohmann, D ; Giannopoulou, C ; Ansorge, S</creatorcontrib><description>OBJECTIVES: in patients with ST and bone metastases (BM) or with MM, SREs are serious and common complications impacting life expectancy and quality of life. This exploratory and descriptive analysis estimated the time from diagnosis to occurrence of first and subsequent SRE in patients with early versus late treatment initiation with SPA. METHODS: This was a retrospective analysis of a German sick-fund claims database (covering -4 million patients) which includes data from 2007 to 2015. Patients with a diagnosis of ST coded with at least two outpatient or one inpatient diagnoses and newly diagnosed with BM after 07/2011 and patients newly diagnosed with MM after 07/2011, aged >18 years were included. All patients received either denosumab or bisphosphonates within 9 months from study inclusion. The study described the time from BM or MM diagnosis to occurrence of first and subsequent SRE in patients with early (<3 months [m]) versus late (4-9m) treatment initiation with SPA. RESULTS: A total of 1,144 patients were analyzed, 949 started treatment early and 195 late. Relevant baseline characteristics in early versus late initiators: mean age (70.1 versus 69.9 years), SRE present (25.7% versus 24.6%), osteoporosis (20.7% versus 12.8%), renal disease (17.1% versus 23.1%). The median (95% confidence interval) time to first SRE was 23m (16; 32) and 6m (3; 13) for the early and late initiators, respectively; the median time to second SRE was 41m (36; NA) and 21m (13; NA), respectively. A similar pattern was observed for the third SRE that did not reach median time. CONCLUSIONS: In this exploratory, descriptive analysis, the median time to first and subsequent SRE was shorter for late versus early initiators. This suggests that patients initiating SPA earlier have lower SRE rates versus patients who may be initiating treatment later as a response to an SRE.</description><identifier>ISSN: 1098-3015</identifier><identifier>EISSN: 1524-4733</identifier><identifier>DOI: 10.1016/j.jval.2017.08.113</identifier><language>eng</language><publisher>Lawrenceville: Elsevier Science Ltd</publisher><subject>Bisphosphonates ; Bones ; Confidence intervals ; Diagnosis ; Inpatient care ; Kidney diseases ; Life expectancy ; Life span ; Medical diagnosis ; Metastases ; Metastasis ; Monoclonal antibodies ; Multiple myeloma ; Myeloma ; Newly diagnosed ; Osteoporosis ; Patients ; Quality of life ; Solid tumors ; Targeted cancer therapy ; Tumors</subject><ispartof>Value in health, 2017-10, Vol.20 (9), p.A417</ispartof><rights>Copyright Elsevier Science Ltd. Oct/Nov 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1643-c932d94ec27c58ea9f58d0db7b765ce69070be2b94b386c8e2904b2a2323866a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902,30976</link.rule.ids></links><search><creatorcontrib>Intorcia, M</creatorcontrib><creatorcontrib>Hohmann, D</creatorcontrib><creatorcontrib>Giannopoulou, C</creatorcontrib><creatorcontrib>Ansorge, S</creatorcontrib><title>Occurrence Of Skeletal-Related Events (SRE) In Patients With Solid Tumors (ST) And Multiple Myeloma (MM) In Germany: Early Versus Late Initiation of Sre Preventative Agents (SPA)</title><title>Value in health</title><description>OBJECTIVES: in patients with ST and bone metastases (BM) or with MM, SREs are serious and common complications impacting life expectancy and quality of life. This exploratory and descriptive analysis estimated the time from diagnosis to occurrence of first and subsequent SRE in patients with early versus late treatment initiation with SPA. METHODS: This was a retrospective analysis of a German sick-fund claims database (covering -4 million patients) which includes data from 2007 to 2015. Patients with a diagnosis of ST coded with at least two outpatient or one inpatient diagnoses and newly diagnosed with BM after 07/2011 and patients newly diagnosed with MM after 07/2011, aged >18 years were included. All patients received either denosumab or bisphosphonates within 9 months from study inclusion. The study described the time from BM or MM diagnosis to occurrence of first and subsequent SRE in patients with early (<3 months [m]) versus late (4-9m) treatment initiation with SPA. RESULTS: A total of 1,144 patients were analyzed, 949 started treatment early and 195 late. Relevant baseline characteristics in early versus late initiators: mean age (70.1 versus 69.9 years), SRE present (25.7% versus 24.6%), osteoporosis (20.7% versus 12.8%), renal disease (17.1% versus 23.1%). The median (95% confidence interval) time to first SRE was 23m (16; 32) and 6m (3; 13) for the early and late initiators, respectively; the median time to second SRE was 41m (36; NA) and 21m (13; NA), respectively. A similar pattern was observed for the third SRE that did not reach median time. CONCLUSIONS: In this exploratory, descriptive analysis, the median time to first and subsequent SRE was shorter for late versus early initiators. This suggests that patients initiating SPA earlier have lower SRE rates versus patients who may be initiating treatment later as a response to an SRE.</description><subject>Bisphosphonates</subject><subject>Bones</subject><subject>Confidence intervals</subject><subject>Diagnosis</subject><subject>Inpatient care</subject><subject>Kidney diseases</subject><subject>Life expectancy</subject><subject>Life span</subject><subject>Medical diagnosis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Multiple myeloma</subject><subject>Myeloma</subject><subject>Newly diagnosed</subject><subject>Osteoporosis</subject><subject>Patients</subject><subject>Quality of life</subject><subject>Solid tumors</subject><subject>Targeted cancer therapy</subject><subject>Tumors</subject><issn>1098-3015</issn><issn>1524-4733</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><recordid>eNotUctOwzAQjBBIQOEHOK3EhR4S_MiTW4VKQWrVihY4Wo6zhQQ3KXZSKb_FF-IAp33Nzqx2PO-KkoASGt9WQXWQOmCEJgFJA0r5kXdGIxb6YcL5sctJlvqc0OjUO7e2IoTEnEVn3vdSqc4YrBXCcgvrT9TYSu0_o5YtFjA9YN1auFk_T8fwVMNKtuVv561sP2Dd6LKATbdrzIDZjGFSF7DodFvuNcKiR93sJNwsFr_LMzQ7Wfd3MJVG9_CKxnYW5k7ITcu2dNxNDY07wyCsDA7arndAmLz_n7GajC-8k63UFi__48h7eZhu7h_9-XL2dD-Z-4rGIfdVxlmRhahYoqIUZbaN0oIUeZIncaQwzkhCcmR5FuY8jVWKLCNhziTjzNWx5CPv-o93b5qvDm0rqqYztZMUzD04YTFPE4difyhlGmsNbsXelDtpekGJGLwRlRi8EYM3gqTCrfIf7LWCLg</recordid><startdate>201710</startdate><enddate>201710</enddate><creator>Intorcia, M</creator><creator>Hohmann, D</creator><creator>Giannopoulou, C</creator><creator>Ansorge, S</creator><general>Elsevier Science Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope></search><sort><creationdate>201710</creationdate><title>Occurrence Of Skeletal-Related Events (SRE) In Patients With Solid Tumors (ST) And Multiple Myeloma (MM) In Germany: Early Versus Late Initiation of Sre Preventative Agents (SPA)</title><author>Intorcia, M ; Hohmann, D ; Giannopoulou, C ; Ansorge, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1643-c932d94ec27c58ea9f58d0db7b765ce69070be2b94b386c8e2904b2a2323866a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Bisphosphonates</topic><topic>Bones</topic><topic>Confidence intervals</topic><topic>Diagnosis</topic><topic>Inpatient care</topic><topic>Kidney diseases</topic><topic>Life expectancy</topic><topic>Life span</topic><topic>Medical diagnosis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Multiple myeloma</topic><topic>Myeloma</topic><topic>Newly diagnosed</topic><topic>Osteoporosis</topic><topic>Patients</topic><topic>Quality of life</topic><topic>Solid tumors</topic><topic>Targeted cancer therapy</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Intorcia, M</creatorcontrib><creatorcontrib>Hohmann, D</creatorcontrib><creatorcontrib>Giannopoulou, C</creatorcontrib><creatorcontrib>Ansorge, S</creatorcontrib><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><jtitle>Value in health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Intorcia, M</au><au>Hohmann, D</au><au>Giannopoulou, C</au><au>Ansorge, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Occurrence Of Skeletal-Related Events (SRE) In Patients With Solid Tumors (ST) And Multiple Myeloma (MM) In Germany: Early Versus Late Initiation of Sre Preventative Agents (SPA)</atitle><jtitle>Value in health</jtitle><date>2017-10</date><risdate>2017</risdate><volume>20</volume><issue>9</issue><spage>A417</spage><pages>A417-</pages><issn>1098-3015</issn><eissn>1524-4733</eissn><abstract>OBJECTIVES: in patients with ST and bone metastases (BM) or with MM, SREs are serious and common complications impacting life expectancy and quality of life. This exploratory and descriptive analysis estimated the time from diagnosis to occurrence of first and subsequent SRE in patients with early versus late treatment initiation with SPA. METHODS: This was a retrospective analysis of a German sick-fund claims database (covering -4 million patients) which includes data from 2007 to 2015. Patients with a diagnosis of ST coded with at least two outpatient or one inpatient diagnoses and newly diagnosed with BM after 07/2011 and patients newly diagnosed with MM after 07/2011, aged >18 years were included. All patients received either denosumab or bisphosphonates within 9 months from study inclusion. The study described the time from BM or MM diagnosis to occurrence of first and subsequent SRE in patients with early (<3 months [m]) versus late (4-9m) treatment initiation with SPA. RESULTS: A total of 1,144 patients were analyzed, 949 started treatment early and 195 late. Relevant baseline characteristics in early versus late initiators: mean age (70.1 versus 69.9 years), SRE present (25.7% versus 24.6%), osteoporosis (20.7% versus 12.8%), renal disease (17.1% versus 23.1%). The median (95% confidence interval) time to first SRE was 23m (16; 32) and 6m (3; 13) for the early and late initiators, respectively; the median time to second SRE was 41m (36; NA) and 21m (13; NA), respectively. A similar pattern was observed for the third SRE that did not reach median time. CONCLUSIONS: In this exploratory, descriptive analysis, the median time to first and subsequent SRE was shorter for late versus early initiators. This suggests that patients initiating SPA earlier have lower SRE rates versus patients who may be initiating treatment later as a response to an SRE.</abstract><cop>Lawrenceville</cop><pub>Elsevier Science Ltd</pub><doi>10.1016/j.jval.2017.08.113</doi><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 1098-3015
ispartof	Value in health, 2017-10, Vol.20 (9), p.A417
issn	1098-3015 1524-4733
language	eng
recordid	cdi_proquest_journals_2113726387
source	Applied Social Sciences Index & Abstracts (ASSIA); Elsevier
subjects	Bisphosphonates Bones Confidence intervals Diagnosis Inpatient care Kidney diseases Life expectancy Life span Medical diagnosis Metastases Metastasis Monoclonal antibodies Multiple myeloma Myeloma Newly diagnosed Osteoporosis Patients Quality of life Solid tumors Targeted cancer therapy Tumors
title	Occurrence Of Skeletal-Related Events (SRE) In Patients With Solid Tumors (ST) And Multiple Myeloma (MM) In Germany: Early Versus Late Initiation of Sre Preventative Agents (SPA)
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T12%3A26%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Occurrence%20Of%20Skeletal-Related%20Events%20(SRE)%20In%20Patients%20With%20Solid%20Tumors%20(ST)%20And%20Multiple%20Myeloma%20(MM)%20In%20Germany:%20Early%20Versus%20Late%20Initiation%20of%20Sre%20Preventative%20Agents%20(SPA)&rft.jtitle=Value%20in%20health&rft.au=Intorcia,%20M&rft.date=2017-10&rft.volume=20&rft.issue=9&rft.spage=A417&rft.pages=A417-&rft.issn=1098-3015&rft.eissn=1524-4733&rft_id=info:doi/10.1016/j.jval.2017.08.113&rft_dat=%3Cproquest_cross%3E2113726387%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1643-c932d94ec27c58ea9f58d0db7b765ce69070be2b94b386c8e2904b2a2323866a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2113726387&rft_id=info:pmid/&rfr_iscdi=true